Names Chris Wolven Chief Operating Officer
SCOTTSDALE, Ariz., Jan. 16, 2019 (GLOBE NEWSWIRE)
-- Item 9 Labs Corp. (INLB) (Item 9 Labs or
the Company), a leading developer and manufacturer of innovative
cannabis products and proprietary delivery platforms, today
announced Chris Wolven is joining the executive team as Chief
Operating Officer.
Wolven previously served as Brand Chef at Fox Restaurant Concepts, a culinary powerhouse renowned for its boutique brands and thoughtfully curated dining experiences. The group has an impressive lineup of more than 50 restaurant locations throughout the nation.
âWe are excited to have Chris join our team. His passion for quality ingredients, a high-level of service, and superior customer experience compliments our mission and vision,â stated Sara Gullickson, CEO of Item 9 Labs. âChris has opened establishments throughout the country with a gold standard for excellence, which is exactly what we need as we expand our operations.â
Wolven was responsible for operations and food development for seven of the 15 brands under Fox Restaurant Concepts, spanning ten locations with over 1,000 employees. He oversaw creative development, financial planning, the building and implementation of systems, as well as operational wellbeing. Wolvenâs region brought in over $50 million in annual revenue.
âItâs an absolute honor to be working with some of the industryâs top professionals at an organization dedicated to crafting distinctive and progressive cannabis brands,â said Chris Wolven, Chief Operating Officer.
Item 9 Labs is an all-encompassing cannabis enterprise. It will be operating as licensed dispensaries, cultivation, and manufacturing facilities in six to ten U.S. markets by the end of 2019.
The Company currently operates an indoor cultivation facility zoned on 50 acres in Arizona and has joint ventures in medical cannabis cultivation and processing facility Strive Wellness of Nevada, LLC, and dispensary Strive Life North Dakota.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Companyâs proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industryâs first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of todayâs modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking
Statement:
This press release contains forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties, including, but not limited to, risks and effects of
legal and administrative proceedings and governmental regulation,
especially in a foreign country, future financial and operational
results, competition, general economic conditions, proposed
transactions that are not legally binding obligations of the
company and the ability to manage and continue growth. Should one
or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual outcomes may vary
materially from those indicated. Important factors that could cause
actual results to differ materially from the forward-looking
statements we make in this news release include the introduction of
new technology, market conditions and those set forth in reports or
documents we file from time to time with the SEC. We undertake no
obligation to revise or update such statements to reflect current
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
Media Contact:
Neko Catanzaro
Proven Media
[email protected]
(401) 484-4980
Investor Contact:
Jeffrey Rassas
Item 9 Labs Corp.
[email protected]
(602) 463-4246